Table 1.
Schedule of enrolment, treatments, and assessments.
| Study period | Screening | Baseline, week 0 | Treatment period, week 1–4 | Post-treatment, week 4 | Follow-up, week 8 |
|---|---|---|---|---|---|
| Enrolment | |||||
| Eligibility screening | • | ||||
| Informed consent | • | ||||
| Random allocation | • | ||||
| Treatment | • | ||||
| Outcome assessment | |||||
| (1) EORTC QLQ-CIPN20 | • | • | • | ||
| (2) NCI CTCAE V5.0 | • | • | • | ||
| (3) EORTC QLQ-C30 | • | • | • | ||
| Safety assessment | • | • | • | • |
•, Required; EORTC QLQ-CIPN20, the European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Chemotherapy-induced peripheral neuropathy 20; NCI CTCAE V5.0, National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0; EORTC QLQ-C30, the European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30.